Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).

Geoffrey J. Lindeman,Rebecca Bowen,Katarzyna J. Jerzak,Xinni Song,Thomas Decker,Frances M. Boyle,Steven L. McCune,Anne C Armstrong,Catherine Shannon,Gianfilippo Bertelli,Tharu M. Fernando,Rupal Desai,Kushagra Gupta,Jerry Y. Hsu,Aulde Flechais,Aditya Bardia

Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).

2021

Geoffrey J. Lindeman
Rebecca Bowen
Katarzyna J. Jerzak
Xinni Song
Thomas Decker
Frances M. Boyle
Steven L. McCune
Anne C Armstrong
Catherine Shannon
Gianfilippo Bertelli
Tharu M. Fernando
Rupal Desai
Kushagra Gupta
Jerry Y. Hsu
Aulde Flechais
Aditya Bardia

1004Background: For patients (pts) with ER-positive, HER2-negative MBC, CDK4/6 inhibitors + endocrine therapy (ET) is standard first-line treatment, with single-agent ET considered for second-line....

Keywords:

Metastatic breast cancer
Oncology
Medicine
Estrogen receptor
third line
Ven
Internal medicine
Phases of clinical research
Fulvestrant
HER2 negative
Venetoclax

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations